Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.30 USD
Change Today +0.90 / 37.50%
Volume 7.8K
VGEN On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

vaccinogen inc (VGEN) Snapshot

Open
$2.38
Previous Close
$2.40
Day High
$3.40
Day Low
$2.20
52 Week High
02/4/15 - $4.90
52 Week Low
06/5/15 - $1.65
Market Cap
121.9M
Average Volume 10 Days
6.5K
EPS TTM
--
Shares Outstanding
36.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VACCINOGEN INC (VGEN)

Related News

No related news articles were found.

vaccinogen inc (VGEN) Related Businessweek News

No Related Businessweek News Found

vaccinogen inc (VGEN) Details

Vaccinogen Inc., a biotechnology company, focuses on the development and commercialization of cancer vaccines and immunotherapeutic products for cancers in the United States. It primarily offers OncoVAX, a cancer vaccine for the post-surgical treatment of Stage II colon cancer. The company was founded in 2007 and is headquartered in Baltimore, Maryland.

24 Employees
Last Reported Date: 04/15/15
Founded in 2007

vaccinogen inc (VGEN) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $534.8K
Founder, Chairman Emeritus, Special Advisor, ...
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2014.

vaccinogen inc (VGEN) Key Developments

Vaccinogen, Inc. Presents at Marcum Microcap Conference 2015, May-28-2015 04:00 PM

Vaccinogen, Inc. Presents at Marcum Microcap Conference 2015, May-28-2015 04:00 PM. Venue: Grand Hyatt New York, Park Avenue at Grand Central, New York, NY 10017, United States.

Vaccinogen, Inc. Replaces Benjamin S. Carson with Andrew L. Tussing as Chairman

Vaccinogen, Inc. announced that its Board of Directors has unanimously elected Co-founder, President, Chief Executive Officer and current Director, Andrew L. Tussing, to the role of Chairman of the Board. Mr. Tussing replaces Benjamin S. Carson, Sr., MD, who resigned from the Board and his role as Chairman and a member of the company's Medical Advisory Board role to pursue his candidacy for the President of the United States via the Republican nomination.

Vaccinogen, Inc. announced delayed annual 10-K filing

On 04/01/2015, Vaccinogen, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VGEN:US $3.30 USD +0.90

VGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VGEN.
View Industry Companies
 

Industry Analysis

VGEN

Industry Average

Valuation VGEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VACCINOGEN INC, please visit www.vaccinogeninc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.